Conservation of oncofetal antigens on human embryonic stem cells enables discovery of monoclonal antibodies against cancer

Conservation of oncofetal antigens on human embryonic stem cells enables discovery of monoclonal antibodies against cancer
Title:
Conservation of oncofetal antigens on human embryonic stem cells enables discovery of monoclonal antibodies against cancer
Other Titles:
Scientific Reports
Keywords:
Publication Date:
02 August 2018
Citation:
Tan, H.L., Yong, C., Tan, B.Z. et al. Conservation of oncofetal antigens on human embryonic stem cells enables discovery of monoclonal antibodies against cancer. Sci Rep 8, 11608 (2018). https://doi.org/10.1038/s41598-018-30070-z
Abstract:
Monoclonal antibodies (mAbs) are used as targeted therapies against cancers. These mAbs kill cancer cells via various mechanisms of actions. In this study, human embryonic stem cells (hESCs) was used as the immunogen to generate a panel of antibodies. From this panel of mAbs, A19 was found to bind both hESC and various cancer cell lines. The antigen target of A19 was identified as Erbb-2 and glycan analysis showed that A19 binds to a N-glycan epitope on the antigen. A19 was elucidated to internalize into cancer cells following binding to Erbb-2 and hence developed as an antibody-drug conjugate (ADC). Using ADC as the mechanism of action, A19 was able to kill cancer cells in vitro and delayed the onset of tumour formation in mice xenograft model. When compared to Herceptin, A19 binds to different isoforms of Erbb-2 and does not compete with Herceptin for the same epitope. Hence, A19 has the potential to be developed as an alternative targeted therapeutic agent for cancers expressing Erbb-2.
License type:
http://creativecommons.org/licenses/by/4.0/
Funding Info:
This research is supported by Bioprocessing Technology Institute, A*STAR
Description:
ISSN:
2045-2322
Files uploaded:

File Size Format Action
s41598-018-30070-z.pdf 1.37 MB PDF Open